Solerija Pharma Reports January Exercise

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from was processed by Pulse News Wire on February 2, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Solerija Pharma Reports January Exercise Status of Warrant Issue

Source disclosure: February 02, 2026 Solasia Pharma K.K. [4597.T] TOKYO, Feb 02 (Pulse News Wire) – Solasia Pharma K.k. (4597.T) reported the exercise status of its warrant issue with price adjustment clause for January 2026. According to the report, the number of warrants exercised during the month was 55,000 out of 10.11% total warrants issued, representing a ratio of [figure]%. As of the end of December 2025, there were 92,499 unexercised warrants corresponding to 9,249,900 share